title: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
abstract: Selumetinib is a potent, selective MEK inhibitor with efficacy in several tumor models. This study compared selumetinib with capecitabine in patients with advanced or metastatic pancreatic cancer who had been pretreated with a gemcitabine-based regimen. In this randomized, multicenter phase II study (NCT00372944), patients received either 100 mg oral selumetinib twice daily or 1,250 mg/m(2) oral capecitabine twice daily for 2 weeks followed by a 1-week break, given in 3-weekly cycles. The primary endpoint was overall survival. In all 70 patients were randomized. The median survival was 5.4 months in the selumetinib group and 5.0 months in the capecitabine group (hazard ratio 1.03; two-sided 80% confidence interval = 0.68,1.57; P = 0.92). Disease progression events occurred in 84% and 88% of patients in the selumetinib and capecitabine treatment groups, respectively. Gastrointestinal adverse events (nausea, vomiting and diarrhea) were commonly observed in both treatment groups. Other frequently reported adverse events were acneiform dermatitis and peripheral edema with selumetinib, and palmar-plantar erythrodysaesthesia with capecitabine. There was no statistically significant difference in overall survival between selumetinib and capecitabine as second-line treatment in patients with advanced pancreatic cancer. Selumetinib was well tolerated with a manageable safety profile.
authors: Department of Oncology, St. László Hospital, Gyáli út 5-7, 1097, Budapest, Hungary. bodokygy@hungarnet.hu
authors: György
authors: G
authors: Bodoky
authors: Constanta
authors: C
authors: Timcheva
authors: David Robert
authors: DR
authors: Spigel
authors: Phillip Joseph
authors: PJ
authors: La Stella
authors: Tudor Eliade
authors: TE
authors: Ciuleanu
authors: G
authors: G
authors: Pover
authors: N C
authors: NC
authors: Tebbutt
references: J Clin Oncol. 2007 Oct 20;25(30):4787-92
references: 17947726
references: Cancer Chemother Pharmacol. 2009 May;63(6):1141-5
references: 18839175
references: Oncology. 2006;71(3-4):159-63
references: 17646699
references: J Clin Oncol. 2008 May 1;26(13):2139-46
references: 18390968
references: J Clin Oncol. 2009 Jan 10;27(2):193-8
references: 19047305
references: Cancer Invest. 2005;23(1):9-12
references: 15779862
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Br J Cancer. 2003 Apr 22;88(8):1180-4
references: 12698181
references: J Clin Oncol. 2005 Oct 1;23(28):7199-206
references: 16192604
references: Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6
references: 17143253
references: Oncology. 2004;67(2):93-7
references: 15539911
references: Nucleic Acids Res. 1988 Aug 25;16(16):7773-82
references: 3047672
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Ann Oncol. 2007 Jun;18 Suppl 6:vi124-7
references: 17591805
references: Oncology. 2009;76(4):270-4
references: 19258727
references: Biochim Biophys Acta. 2007 Aug;1773(8):1248-55
references: 17194493
references: Pharm Stat. 2009 Oct-Dec;8(4):333-45
references: 19180520
references: Cancer. 2008 Oct 15;113(8):2046-52
references: 18756532
references: Clin Cancer Res. 2007 Mar 1;13(5):1576-83
references: 17332304
references: Curr Top Med Chem. 2007;7(14):1364-78
references: 17692026
references: Cell. 1988 May 20;53(4):549-54
references: 2453289
references: Br J Cancer. 2006 Feb 27;94(4):481-5
references: 16434988
references: Ann Oncol. 2007 Mar;18(3):581-92
references: 17287242
references: J Clin Oncol. 2002 Jan 1;20(1):160-4
references: 11773165
references: Ann Oncol. 2007 Apr;18(4):745-51
references: 17229775
references: Onkologie. 2009 Mar;32(3):99-102
references: 19295247
references: Anticancer Drugs. 2000 Sep;11(8):635-8
references: 11081455
references: Invest New Drugs. 2005 Aug;23(4):369-75
references: 16012797